Recurrent Cancer Clinical Trials

10 recruiting

Recurrent Cancer Trials at a Glance

10 actively recruiting trials for recurrent cancer are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Heidelberg, Würzburg, and Bonn. Lead sponsors running recurrent cancer studies include Immatics Biotechnologies GmbH, Dana-Farber Cancer Institute, and Centre Leon Berard.

Browse recurrent cancer trials by phase

Treatments under study

About Recurrent Cancer Clinical Trials

Looking for clinical trials for Recurrent Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics US, Inc.375 enrolled21 locationsNCT03686124
Recruiting
Not Applicable

Spatially Fractionated Radiation Treatment for Gynaecological Cancers

Cervical CancerGynecologic CancerRecurrent Cancer
Tata Memorial Hospital20 enrolled1 locationNCT06644846
Recruiting
Phase 1Phase 2

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1Phase 2

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Refractory CancerRecurrent CancerChildhood Cancer+2 more
Australian & New Zealand Children's Haematology/Oncology Group90 enrolled14 locationsNCT06208657
Recruiting
Phase 2

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

Hepatocellular CarcinomaLiver TransplantRecurrent Cancer
University Health Network, Toronto20 enrolled1 locationNCT04204850
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide Vaccines for Solid Tumors

Solid TumorsAdvanced CancerRecurrent Cancer+2 more
Seqker Biosciences, Inc.10 enrolled2 locationsNCT07002203
Recruiting
Phase 1Phase 2

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH145 enrolled24 locationsNCT05958121
Recruiting
Phase 1

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH95 enrolled23 locationsNCT05359445
Recruiting
Phase 2

PREventing Second Cancers With DOSTARlimab

Recurrent CancerSecond CancerPrimary Cancer
Centre Leon Berard400 enrolled5 locationsNCT05855811
Recruiting

Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors

Stereotactic Body Radiation TherapyRecurrent CancerThoracic Tumor+1 more
Peking University Third Hospital40 enrolled1 locationNCT05189054